EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Current Evidence and Future Directions for Colchicine in the Prevention of Atherosclerotic Cardiovascular Disease

Aimée M H van Zelm, Aernoud T L Fiolet, Robert J Hinchliffe, Shirley Jansen, Martin Teraa, Noel C Chan

Thrombosis and Haemostasis · 01.10.2026 · 126 (10) · 0991-1005

DOI: 10.1055/a-2724-4543 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Thrombosis and Haemostasis, erschienen am 01.10.2026. Verfasst von Aimée M H van Zelm und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Vascular Surgery, University Medical Center Utrecht, Utrecht, The Netherlands. Hauptthemen laut MEDLINE: Colchicine, Atherosclerosis, Anti-Inflammatory Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 88 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chronic inflammation plays a key role in the development and progression of atherosclerotic cardiovascular disease (ASCVD) and its complications. Despite the use of blood pressure-, lipid-, and glucose-lowering therapies as well as antithrombotic agents, the lifetime residual cardiovascular (CV) risk in patients with ASCVD remains high. Because chronic inflammation remains an unaddressed risk factor, anti-inflammatory therapy has the potential to further lower residual CV risk in these patients. Low-dose colchicine (0.5 mg daily) has emerged as a promising low-cost oral anti-inflammatory therapy for this indication. In patients with chronic coronary syndrome (CCS), low-dose colchicine was well-tolerated and reduced the risk of myocardial infarction, stroke, coronary revascularization, and CV death. However, trials in patients with acute coronary syndrome (ACS) yielded conflicting results, and two trials in patients with ischemic stroke did not show a benefit. In patients with peripheral artery disease (PAD), preliminary observational data suggested a potential benefit, and a randomized trial is currently underway to examine its efficacy in reducing CV and limb events. The long-term safety data for low-dose colchicine in ASCVD are reassuring. Although pooled data from trials in ASCVD show a small (0.55%) absolute increase in the risk of hospitalization for gastrointestinal events, adverse signals were not observed for serious infection, cancer, or severe myotoxicity. In this article, we review the clinical studies of colchicine that examined its risk–benefit for the prevention of CV events in patients with ASCVD, discuss clinical and research implications, and highlight knowledge gaps.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ColchicineAtherosclerosisAnti-Inflammatory AgentsHumansAnimalsRisk FactorsInflammationTreatment OutcomeCardiovascular DiseasesAcute Coronary Syndrome

Substanzen

ColchicineAnti-Inflammatory Agents

Autor:innen und Institutionen

  • Department of Vascular Surgery, University Medical Center Utrecht, Utrecht, The Netherlands.
  • Department of Cardiology, University Medical Center Utrecht, Utrecht, The Netherlands.
  • Department of Vascular Surgery, University of Bristol, Bristol, United Kingdom.
  • Department of Vascular and Endovascular Surgery, Sir Charles Gairdner Hospital, Perth, Western Australia, Australia.
  • Heart and Vascular Research Institute, Harry Perkins Institute of Medical Research, Perth, Western Australia, Australia.
  • Department of Medicine, McMaster University, Ontario, Canada.

Zitieren

APA

van Zelm, A. M. H., Fiolet, A. T. L., Hinchliffe, R. J., Jansen, S., Teraa, M., & Chan, N. C. (2026). Current Evidence and Future Directions for Colchicine in the Prevention of Atherosclerotic Cardiovascular Disease. Thrombosis and Haemostasis, 126(10), 0991-1005. https://doi.org/10.1055/a-2724-4543

Vancouver

van Zelm AMH, Fiolet ATL, Hinchliffe RJ, Jansen S, Teraa M, Chan NC. Current Evidence and Future Directions for Colchicine in the Prevention of Atherosclerotic Cardiovascular Disease. Thrombosis and Haemostasis. 2026;126(10):0991-1005. doi:10.1055/a-2724-4543

BibTeX
@article{vanZelm2026,
  author = {van Zelm, Aimée M H and Fiolet, Aernoud T L and Hinchliffe, Robert J and Jansen, Shirley and Teraa, Martin and Chan, Noel C},
  title = {Current Evidence and Future Directions for Colchicine in the Prevention of Atherosclerotic Cardiovascular Disease},
  journal = {Thrombosis and Haemostasis},
  year = {2026},
  volume = {126},
  number = {10},
  pages = {0991--1005},
  doi = {10.1055/a-2724-4543}
}
Kostenlos starten →